Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective observational multicenter study providing real-world evidence of fremanezumab treatment outcomes in chronic and episodic migraine patients in routine clinical practice

X
Trial Profile

Prospective observational multicenter study providing real-world evidence of fremanezumab treatment outcomes in chronic and episodic migraine patients in routine clinical practice

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms FINESSE
  • Most Recent Events

    • 18 Apr 2024 Interim Results (cut-off 31-Jan-2023) of Fremanezumab Effectiveness and Tolerability , presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 18 Apr 2024 Interim subgroup (n=140) analysis results presented at the 76th Annual Meeting of the American Academy of Neurology 2024
    • 15 Jun 2023 According to Teva Pharmaceuticals USA media release, data from this trial will be presented at the American Headache Society (AHS) Annual Meeting, held June 15-18 in Austin, Texas.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top